Rhamnan sulfate reduces atherosclerotic plaque formation and vascular inflammation
Copyright © 2022 Elsevier Ltd. All rights reserved..
OBJECTIVE: While lipid-lowering drugs have become a mainstay of clinical therapy these treatments only slow the progression of the disease and can have side effects. Thus, new treatment options are needed to supplement the effects of lipid lowering therapy for treating atherosclerosis. We examined the use of an inexpensive and widely available marine polysaccharide rhamnan sulfate as an oral therapeutic for limiting vascular inflammation and atherosclerosis.
METHODS AND RESULTS: We found rhamnan sulfate enhanced the barrier function of endothelial cells, preventing the deposition of LDL and maintaining barrier function even in the presence of glycocalyx-degrading enzymes. Rhamnan sulfate was also found to bind directly to FGF-2, PDGF-BB and NF-κB subunits with high affinity. In addition, rhamnan sulfate was a potent inhibitor of NF-κB pathway activation in endothelial cells by TNF-α. We treated ApoE-/- mice with a high fat diet for 4 weeks and then an addition 9 weeks of high fat diet with or without rhamnan sulfate. Rhamnan sulfate reduced vascular inflammation and atherosclerosis in both sexes of ApoE-/- mice but had a stronger therapeutic effect in female mice. Oral consumption of rhamnan sulfate induced a significant decrease in cholesterol plasma levels in female mice but not in male mice. In addition, there was a marked reduction in inflammation for female mice in the liver and aortic root in comparison to male mice.
CONCLUSIONS: Rhamnan sulfate has beneficial effects in reducing inflammation, binding growth factors and NF-κB, enhancing endothelial barrier function and reducing atherosclerotic plaque formation in ApoE-/- mice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:291 |
|---|---|
| Enthalten in: |
Biomaterials - 291(2022) vom: 05. Dez., Seite 121865 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patil, Nikita P [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.11.2022 Date Revised 06.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biomaterials.2022.121865 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348461690 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348461690 | ||
| 003 | DE-627 | ||
| 005 | 20231226040256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biomaterials.2022.121865 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348461690 | ||
| 035 | |a (NLM)36332287 | ||
| 035 | |a (PII)S0142-9612(22)00505-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patil, Nikita P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rhamnan sulfate reduces atherosclerotic plaque formation and vascular inflammation |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2022 | ||
| 500 | |a Date Revised 06.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVE: While lipid-lowering drugs have become a mainstay of clinical therapy these treatments only slow the progression of the disease and can have side effects. Thus, new treatment options are needed to supplement the effects of lipid lowering therapy for treating atherosclerosis. We examined the use of an inexpensive and widely available marine polysaccharide rhamnan sulfate as an oral therapeutic for limiting vascular inflammation and atherosclerosis | ||
| 520 | |a METHODS AND RESULTS: We found rhamnan sulfate enhanced the barrier function of endothelial cells, preventing the deposition of LDL and maintaining barrier function even in the presence of glycocalyx-degrading enzymes. Rhamnan sulfate was also found to bind directly to FGF-2, PDGF-BB and NF-κB subunits with high affinity. In addition, rhamnan sulfate was a potent inhibitor of NF-κB pathway activation in endothelial cells by TNF-α. We treated ApoE-/- mice with a high fat diet for 4 weeks and then an addition 9 weeks of high fat diet with or without rhamnan sulfate. Rhamnan sulfate reduced vascular inflammation and atherosclerosis in both sexes of ApoE-/- mice but had a stronger therapeutic effect in female mice. Oral consumption of rhamnan sulfate induced a significant decrease in cholesterol plasma levels in female mice but not in male mice. In addition, there was a marked reduction in inflammation for female mice in the liver and aortic root in comparison to male mice | ||
| 520 | |a CONCLUSIONS: Rhamnan sulfate has beneficial effects in reducing inflammation, binding growth factors and NF-κB, enhancing endothelial barrier function and reducing atherosclerotic plaque formation in ApoE-/- mice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Atherosclerosis | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Marine polysaccharides | |
| 650 | 4 | |a NF-κB pathway | |
| 650 | 4 | |a Rhamnan sulfate | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a rhamnan |2 NLM | |
| 650 | 7 | |a 111018-90-7 |2 NLM | |
| 650 | 7 | |a Sulfates |2 NLM | |
| 650 | 7 | |a Apolipoproteins E |2 NLM | |
| 700 | 1 | |a Gómez-Hernández, Almudena |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Fuming |e verfasserin |4 aut | |
| 700 | 1 | |a Cancel, Limary |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Xu |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Lufeng |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Takematsu, Eri |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Emily Y |e verfasserin |4 aut | |
| 700 | 1 | |a Le, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Fisher, Megan E |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez-Rodriguez, Agueda |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Monzon, Carmelo |e verfasserin |4 aut | |
| 700 | 1 | |a Tunnell, James |e verfasserin |4 aut | |
| 700 | 1 | |a Tarbell, John |e verfasserin |4 aut | |
| 700 | 1 | |a Linhardt, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Aaron B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomaterials |d 1989 |g 291(2022) vom: 05. Dez., Seite 121865 |w (DE-627)NLM012732516 |x 1878-5905 |7 nnns |
| 773 | 1 | 8 | |g volume:291 |g year:2022 |g day:05 |g month:12 |g pages:121865 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biomaterials.2022.121865 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 291 |j 2022 |b 05 |c 12 |h 121865 | ||